title: Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1.
abstract: Alternate prime/boost vaccination regimens employing recombinant replication-deficient adenovirus or MVA, expressing Influenza A virus nucleoprotein and matrix protein 1, induced antigen-specific T cell responses in intradermally (ID) vaccinated mice; with the strongest responses resulting from Ad/MVA immunization. In BALB/C mice the immunodominant response was shifted from the previously identified immunodominant epitope to a novel epitope when the antigen was derived from A/Panama/2007/1999 rather than A/PR/8. Alternate immunization routes did not affect the magnitude of antigen-specific systemic IFN-γ response, but higher CD8(+) T-cell IFN-γ immune responses were seen in the bronchoalveolar lavage following intransal (IN) boosting after intramuscular (IM) priming, whilst higher splenic antigen-specific CD8(+) T cell IFN-γ was seen following IM boosting. Partial protection against heterologous influenza virus challenge was achieved following either IM/IM or IM/IN but not ID/ID immunization. These data may be of relevance for the design of optimal immunization regimens for human influenza vaccines, especially for influenza-naïve infants.
authors.affiliation: The Jenner Institute, University of Oxford, Oxford, United Kingdom. teresa.lambe@ndm.ox.ac.uk
authors.forename: Teresa
authors.initials: T
authors.lastname: Lambe
authors.forename: John B
authors.initials: JB
authors.lastname: Carey
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Li
authors.forename: Alexandra J
authors.initials: AJ
authors.lastname: Spencer
authors.forename: Arjan
authors.initials: A
authors.lastname: van Laarhoven
authors.forename: Caitlin E
authors.initials: CE
authors.lastname: Mullarkey
authors.forename: Anto
authors.initials: A
authors.lastname: Vrdoljak
authors.forename: Anne C
authors.initials: AC
authors.lastname: Moore
authors.forename: Sarah C
authors.initials: SC
authors.lastname: Gilbert
mesh_terms: D000256:Adenoviridae / Q000235:genetics / Q000276:immunology*; D000281:Administration, Intranasal; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D005260:Female; D005822:Genetic Vectors / Q000235:genetics / Q000378:metabolism; D007117:Immunization, Secondary; D007252:Influenza Vaccines / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D029521:Alphainfluenzavirus / Q000276:immunology* / Q000378:metabolism; D007271:Injections, Intradermal; D007371:Interferon-gamma / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D019590:Nucleocapsid Proteins; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control; D016601:RNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D013154:Spleen / Q000166:cytology / Q000378:metabolism; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology*; D014758:Viral Core Proteins / Q000235:genetics / Q000378:metabolism; D014763:Viral Matrix Proteins / Q000235:genetics / Q000378:metabolism
chemical_list: D016207:Cytokines; D007252:Influenza Vaccines; C488936:M1 protein, Influenza A virus; C048842:NP protein, Influenza A virus; D019590:Nucleocapsid Proteins; D016601:RNA-Binding Proteins; D014758:Viral Core Proteins; D014763:Viral Matrix Proteins; D007371:Interferon-gamma